Bruce Booth - 12 Jun 2025 Form 4 Insider Report for Sionna Therapeutics, Inc. (SION)

Reporting relationship: Director
Issuer ticker: SION
Reported as of: 12 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2025, 17:06:39 UTC
Prior SEC filing: 23 May 2025
Next SEC filing: 26 Jun 2025
Source filing: View source filing
Reporting owner signature: Ommer Chohan, Attorney-in-Fact

Key filing fact

Bruce Booth filed Form 4 for Sionna Therapeutics, Inc. (SION) on 16 Jun 2025.

Key facts

This page summarizes Bruce Booth's Form 4 filing for Sionna Therapeutics, Inc. (SION).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2025, 17:06.

Change

Previous filing in this sequence was filed on 23 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001451612 Primary reporting owner

Booth Bruce

Relationship: Director
Address: C/O SIONNA THERAPEUTICS, INC., 21 HICKORY DRIVE, SUITE 500, WALTHAM
Signature: Ommer Chohan, Attorney-in-Fact
Signature date: 16 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SION transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +19,959
Change %
Price: $0.000000
Shares after: 19,959
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,959
Exercise price: $16.99
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Footnote F2

This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.